| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC0514 |
| Trial ID | NCT04225676 |
| Disease | Acute Lymphoblastic Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Kymriah|Tisagenlecleucel |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Terminated |
| Title | Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) |
| Year | 2020 |
| Country | United States |
| Company sponsor | Novartis Pharmaceuticals |
| Other ID(s) | CCTL019BUS03 |
| Cohort 1 | |||||||||||||||||
|
|||||||||||||||||